SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Clinical trial NCT05163080 · UNKNOWN

Trial details

NCT number: NCT05163080
Sponsor: MimiVax, LLC
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Newly Diagnosed Glioblastoma

Start date: 2021-11-18
Primary completion: 2024-08-18
Enrollment: 247

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.